Haseeb Ahmad: Comprehensive genomic profiling could help improve treatment and reduce costs for healthcare systems.

According to Haseeb Ahmad, President, Europe at Novartis on LinkedIn:

“Up to 40% of cancer patients receive inefficient treatment. Comprehensive genomic profiling (CGP) could help improve treatment for those patients and reduce costs for healthcare systems, but it remains inaccessible to many in Europe.
To Reimagine Medicine and realise the ambitions of Europe’s Beating Cancer Plan, I believe we must increase routine clinical access and reimbursement of CGP. This is why I’m excited that we at Novartis have partnered with several other organisations to form the European Coalition for Comprehensive Genomic Profiling (ECGP) to spread awareness of the importance of genomic testing for the future of our healthcare systems.

Take breast cancer, for example, the most common cancer among European women, with more than 355,000 new cases annually. Researchers have found that CGP helps inform more appropriate treatment decisions in patients with HR+/HER2+ breast cancer and can save EUR 1,238 per patient.
My Novartis colleague Secilia Schott, Global Head Precision Diagnostics, said, “Europe can lead the advancement and application of CGP to address complex healthcare requirements of populations at large and to improve treatment outcomes of its citizens.”
I believe she is right. Europe has an opportunity to lead. Do you?”

For details click here.
Source: Haseeb Ahmad/LinkedIn